Showing results (61-70 of 439) with videos related to
Sort By:
Pageof 44
Oncotargets and Therapy|April 10, 2013
Systematic review of dasatinib in chronic myeloid leukemiaMassimo Breccia, Adriano Salaroli, Matteo Molica, et al.Expert Opinion on Pharmacotherapy|July 4, 2014
Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacyMassimo Breccia, Matteo Molica, Irene Zacheo, et al.Hematological Oncology|December 10, 2015
Impact of exclusion criteria for the DASISION and ENESTnd trials in the front-line treatment of a 'real-life' patient population with chronic myeloid leukaemiaRoberto Latagliata, Ida Carmosino, Federico Vozella, et al.Future Oncology (London, England)|February 12, 2025
Asciminib in the treatment of chronic myeloid leukemia in chronic phaseAlessandro Costa, Emilia Scalzulli, Maria Laura Bisegna, et al.Cancers|October 13, 2021
Philadelphia-Negative Chronic Myeloproliferative Neoplasms during the COVID-19 Pandemic: Challenges and Future ScenariosFrancesca Palandri, Massimo Breccia, Valerio De Stefano, et al.Frontiers in Oncology|April 2, 2021
Dosing Strategies for Improving the Risk-Benefit Profile of Ponatinib in Patients With Chronic Myeloid Leukemia in Chronic PhaseFausto Castagnetti, Fabrizio Pane, Gianantonio Rosti, et al.Expert Review of Hematology|February 8, 2021
Optimizing health-related quality of life in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitorsFabio Efficace, Marco Vignetti, Francesco Sparano, et al.International Journal of Hematology|August 5, 2022
Asciminib as a third line option in chronic myeloid leukemiaAlessandro Laganà, Emilia Scalzulli, Ida Carmosino, et al.Frontiers in Oncology|March 29, 2021
Clinical and Psychological Factors to Consider in Achieving Treatment-Free Remission in Patients With Chronic Myeloid LeukemiaMassimo Breccia, Elisabetta Abruzzese, Mario Annunziata, et al.Current Cancer Drug Targets|June 15, 2022
Future Management of Chronic Myeloid Leukemia: From Dose Optimization to New AgentsMassimo Breccia, Emilia Scalzulli, Sara Pepe, et al.Pageof 44